Human & Experimental Toxicology
Human and Experimental Toxicology (HET), an international, peer-reviewed, open access journal, is dedicated to publishing nonclinical and clinical original research papers and in-depth reviews that comprehensively cover functional, biochemical, and structural disorders in toxicology. The principal aim of HET is to publish timely high impact hypothesis driven scholarly work with an international scope.
The journal publishes on:
- Structural, functional, biochemical, and molecular effects of toxic agents
- Studies that address mechanisms/modes of toxicity
- Safety evaluation of novel chemical, biotechnologically-derived products, and nanomaterials for human health assessment including statistical and mechanism-based approaches
- Novel methods or approaches to research on animal and human tissues (medical and veterinary patients) investigating the functional, biochemical, and structural disorder
- In vitro techniques, particularly those supporting alternative methods
- Novel approaches exploring e.g. adverse outcome pathways, also in the context of risk assessment of chemicals
Papers will be judged based on scientific originality and contribution to the field and quality and subject matter. Papers describing effects on humans or experimental animals only of local interests; it is important that the results can be generalized to wider audiences and applications. Authors must clearly identify chemically the material tested and briefly explain what novel toxic effect (s) or toxic mechanism (s) of the chemical is being reported and what their significance is.
HET does not accept case reports and case studies. HET does not accept papers on herbal or other extracts unless sufficient chemical characterization of the material under investigation is supplied. HET does not publish routine toxicological studies without an aim to define novel mechanisms of toxicity. The same applies to studies that utilize excessive doses of chemicals/toxicants without any relevance with the human situation.
Open access information
From January 2022, HET will become a fully open access journal. All articles that are accepted for publication will be subject to an open access article processing charge (APC) of 2800 USD and will be published with a Creative Commons license.
The APC is payable when a manuscript is accepted after peer review, before it is published. The APC is subject to taxes where applicable. Please see further details here.
Submit your manuscript today at https://mc.manuscriptcentral.com/het.
Human and Experimental Toxicology (HET), an international peer-reviewed journal, is dedicated to publishing nonclinical and clinical original research papers and in-depth reviews that comprehensively cover functional, biochemical, and structural disorders in toxicology. The principal aim of HET is to publish timely high impact hypothesis driven scholarly work with an international scope.
The journal publishes on:
- Structural, functional, biochemical, and molecular effects of toxic agents
- Studies that address mechanisms/modes of toxicity
- Safety evaluation of novel chemical, biotechnologically-derived products, and nanomaterials for human health assessment including statistical and mechanism-based approaches
- Novel methods or approaches to research on animal and human tissues (medical and veterinary patients) investigating the functional, biochemical, and structural disorder
- In vitro techniques, particularly those supporting alternative methods
- Utilization of novel approaches such as exploring adverse outcome pathways e.g. in the service of risk assessment of chemicals
Papers submitted will be judged on the basis of scientific originality and contribution to the field and quality and subject matter. Authors must clearly identify chemically the material tested and briefly explain what novel toxic effect (s) or toxic mechanism (s) of the chemical are being reported and what their significance is.
HET does not accept case reports and case studies. HET does not accept papers on herbal or other extracts unless sufficient chemical characterization of the material under investigation is supplied. HET does not publish routine descriptive toxicological studies which do not address also mechanistic issues of the chemical and the potential applications of the observations of the studies. HET also considers that the selection of doses of experimental studies must carry relevance to human situations, i.e. studies using excessive dose levels are not considered. Radiation biological studies do not belong to the key areas of interests of the journal and will only exceptionally considered.
Manuscripts must address at least one of the following:
- Adverse effects induced by a chemically defined substance and/or the mechanism underlying the toxic phenomenon
- New techniques for assessing potential toxicity, including molecular and systems biology
- Toxicological examinations of specific chemicals, both those showing adverse effects and those demonstrating safety, that meet current standards of scientific acceptability
- Visionary studies exploring new innovative paradigms of toxicology and risk assessment in order to promote the development of the science of toxicology
- Well designed and characterized studies with negative results
Only papers that have not been previously published, that fit in the above mentioned scope, and that have been reviewed by experts in the field before publication will be accepted. Cover letters must state that the paper is new, original, and is not under consideration for publication elsewhere. Papers pending in other journals will not be considered. Co-authors should be individuals who have contributed substantially to the content of the papers. All authors must declare any potential conflict of interest and all financial support.
Please for more information on our author services. If you require further information or help, please visit our support pages: https://us.sagepub.com/en-us/nam/journal-author-gateway
| Kai Savolainen | NanoReflections Oy, Finland |
| A Wallace Hayes | Michigan State University and University of South Florida, USA |
| Marcelo Arbo | Universidade Federal do Rio Grande do Sul, Brazil |
| Arnab Banerjee | Department of Physiology (UG & PG), Serampore College, India |
| Nursen Basaran | Baskent University, Turkiye |
| Barbara D. Beck | Gradient Corporation, Cambridge, USA |
| James Bus | Center for Toxicology and Mechanistic Biology, USA |
| Chunying Chen | National Center for Nanoscience and Technology of China, China |
| Emanuela Corsini | University of Milan, Italy |
| Randall Davis | Oklahoma State University Center for Health Sciences, USA |
| S.J.S. Flora | National Institute of Pharmaceutical Education and Research, India |
| Helmut Greim | Technical University of Munich, Germany |
| Kenneth Hartigan-Go | Department of Health Manila, Philippines |
| Gi-Wook Hwang | Tohoku Medical and Pharmaceutical University, Japan |
| Ivo Iavicoli | University of Naples Federico II, Italy |
| Salmann H. Inayat-Hussain | Petroliam Nasional Berhad, Malaysia |
| Gholamreza Karimi | Department of Pharmacology and Toxicology, Pharmacy School, Mashhad, IRAN |
| William Kluwe | Independent Consultant, Tucson, USA |
| Sijie Lin | Tongji University, China |
| Yasumitsu Ogura | Chiba University, Japan |
| Juan Carlos Quintana | Universidad Cooperativa de Colombia, Colombia |
| Ivonne M.C.M. Rietjens | Wageningen University, Netherlands |
| Saura Sahu | FDA, USA |
| B. Schilter | Nestle Research Center, Switzerland |
| Roel Schins | Heinrich-Heine-University Dusseldorf, Germany |
| Ted Simon | University of Georgia, USA |
| Jone Stanley | Texas A&M University, USA |
| Francisco Moisés Treviño González | Independent, Mexico |
| David Wallace | Oklahoma State University Center for Health Sciences, USA |
| Leila Ahlstrom | Finnish Institute of Occupational Health, Finland |
Manuscript submission guidelines can be accessed on Sage Journals.